Final Program [International Conference on AIDS (14th: 2002: Barcelona, Spain)]

Poster Exhibitions

Wednesday July io

I, - JI

WePeB6o31 Serum biochemical markers of liver fibrosis in
human immunodeficiency virus and hepatitis C
virus-coinfected patients
Y Benhamou, R P Myers, F Imbert-Bismut,
MA Vallantin, S Dominguez, V Thibault,
F Bricaire, T Poynard, C Katlama (France)
WePeB6o32 The seroprevalenc of Viral Hepatitis in HIV
infected persons attending a clinic in the
Southwestern United States
J Post, C Williams, E Post, D Hobohm
(United States)
WePeB6o33 Rates of testing for Hepatitis C virus in HIVinfected injecting drug users receiving medical
care
M R Pfeiffer, J Sackoff, MA Bernard, E Bryan,
S Raj-Singh (United States)
WePeB6o34 Earlier occurrence and increased severity of
Hepatocellular carcinoma in HIV coinfected
patients
M Airoldi M Puoti, R Bruno, P Costa, I El Hamad,
C Filice, F Castelli, F Donato, A Scalzini, G Filice,
G P Carosi (Italy)
WePeB6o35 Hepatitis C RNA levels are unchanged after one
year of effective antiretroviral therapy
FJ Torriani', VAsensi2, C Byrnes', A Carton2,
J A Maradona2, S Melon2, M Ona2, M Blanco2,
J M Arribas2 ('United States; 2Spain)
WePeB6o36 Natural history of chronic hepatitis C: Unusually
rapid progression to liver fibrosis and cirrhosis in
human immunodeficiency virus co-infected
patients
CArizcorreta, C Martinez, F Diaz, R Roldan,
L Martin-Herrera, E Perez-Guzman, J A Giron
(Spain)
WePeB6o37 Interferon alfa-2a and ribavirin "low dose" for the
treatment of HCV infection in HIV co-infected
patients. An open-label, pilot study
E Bernasconi, L Magenta, P Vernazza, C Bellini,
P Schmid, B Miazza, J C Piffaretti, A Cerny
(Switzerland)
WePeB6o38 Analysis of Liver Fibrosis progression markers in
a cohort of 70 HIV/HCV coinfected patients
J Murillas, J Mallolas, J Sanchez-Tapias, R Miquel,
M Garcia-Gasalla, L Bianchi, E Lazzari, J L Blanco,
A Milinkovic, E Martinez, M Lonca, J M Gatell
(Spain)
WePeB6o39 Evolution of HCV quasi-species after initiation of
HAART in HIV-1 co-infected patients
J Babik, M Holodniy (United States)
WePeB6o4o ALT does not predict hepatic fibrosis in HIV/HCV
co-infected patients on antiretroviral therapy
P Kouvatsos, R E Doerfier, W C Woodward
(United States)
WePeB6o41 Hepatitis C virus envelope protein E2 enhances
human lipoprotein binding to cells
S Winschmann, I T Stapleton (United States)
WePeB6o42 Feasibility of interferon-alpha 2b and ribavirin
combination therapy for chronic hepatitis C in
HIV and HCV coinfected patients in a real life
clinical setting
B Jarrousse, M Bentata, P Honord, R Mansouri,
E Gordien, C Alloui, 0 Launay, 0 Lortholary
(France)
WePeB6o43 Impact of INF treatment in the liver activity and
fibrosis in co-infected HCV/HIV patients that are
non-responders
M R T Rodriquez-Torres,Maribel, I R 0 Rodriguez
Orengo, Jose, CR B Rios-Bedoya, Carlos
(Puerto Rico)

WePeB6o44 Impact of HIV co-infection on cell-mediated
responses to HCV-infected women
M C Villacres, M Nowicki, D David, A Kovacs,
D ] Diamond (United States)
WePeB6o45 Haematological toxicity, effect on CD4 cell count
and on body mass index (BMI) of combined
treatment with Peg-Intron~
(1,5g/kg/week)+ribavirin (400 mg/bid) for
hepatitis C virus (HCV) infection in HIV+ patients
on antiretroviral therapy (ART)
C Tural, A Ballesteros D Fuster, R Planas,
H Guardiola, G Sirera, J Romeu, A Salas,
S ]ohnston, J Tor, C Rey-Joly, R Muga, B Clotet
(Spain)
WePeB6o46 Lifestyles of boys and girls, partnership and
sexual risks
Z H Hradilekova, L I Luksik (Slovakia)
WePeB6o47 Incidence of HPV related cervical lesions in HIV
positive/Pap Test negative women undergoing
different antiretroviral treatments
F Lillo, S Lodini, M Origoni, G L Taccagni, F Veglia,
D Ferrari, C Uberti Foppa (Italy)
WePeB6o48 Evaluation of the preparedness for Phase I HIV-1
Vaccine trials in Uganda
E Mugisha, P Kaleebu', L Nielsen', M Sweat2,
G Thiry2, C Schmidt2, B Levings2
('Uganda; 2United States)
WePeB6o49 Safety and immunogenicity of live recombinant
ALVAC-HIV (vCP1521) priming with AIDSVAX~ B/E
gpl2o boosting in Thai HIV-negative adults
S Nitayaphan', P Pitisuttithum', M de Souza',
J Kim2, V Polonis2, W Heyward2, S Gurunathan3,
S Ratto-Kim2, A Brown', A N D Thai AIDS Vaccine
Evaluation Group'
('Thailand; 2 United States; 3France)
WePeB6050 Single dose pharmacokinetics of SPD-756 in
healthy adult volunteers
P F Smith, A Forrest, C H Ballow, J M Adams,
L R Shiveley (United States)
WePeB6o51 Safety and immunogenicity of live recombinant
ALVAC-HIV (vCP 1521) priming with gp 120
boosting in Thai HIV seronegative adults
V Suriyanon', P Thongcharoen',
C Khamboonruang', M de Souza', S Gurunathan2,
S Kim-Ratto2, J Kim2, A M Duliege2, A E Brown',
T the Thai AIDS Vaccine Evaluation Group'
('Thailand; 2 United States)
WePeB6o52 Experience with recruitment of HIV vaccine
volunteers in Trinidad and Tobago
N Jack', H Smith', J Edwards', A Quava',
F Campbell', J Jwang', Y Simon', C Francis',
W Blattner2, F Cleghorn2, C Bartholomew',
C Bartholomew'
('Trinidad and Tobago; 2United States)
WePeB6o53 The first H IV clade A vaccine in a clinical trial:
induction of H IV-specific T cell responses
T Hanke, Al McMichael, M Mwau, I Cebere,
E G T Wee, S Patel, I Sutton, H McShane,
M Brooks, M Tomlinson, I Roberts
(United Kingdom)
WePeB6o54 Pericarditis in AIDS children
R Costa, A Popoiu, G Doros, M Gafencu,
C Popoiu, M Serban (Romania)
WePeC6o55 Dramatic improvement in survival time of adult
Brazilian AIDS patients
I R P Marins', M B Barros', L Flama', S Chen2,
E S Hudes2, C L Szwarcwald', A Barbosa',

P Chequer3, P Teixeira', N Hearst
('Brazil; 2United States; 3Argentina)

Wednesday

166 Final Program